Teva Pharma Reports Positive Topline Results From Ongoing Phase 2a Study Of TEV 408
(RTTNews) - Teva Pharmaceutical Industries (TEVA) announced positive topline results from an ongoing Phase 2a study of TEV 408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease. The study met primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8.
Additional analyses from the ongoing Phase 2a study are underway. The company plans to present further data from the study at a future scientific meeting.
In pre-market trading on NYSE, Teva shares are up 2.96 percent to $37.27.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.